ProQR Pocfratio from 2010 to 2024

PRQR Stock  USD 3.44  0.10  2.82%   
ProQR Therapeutics POCF Ratio yearly trend continues to be relatively stable with very little volatility. POCF Ratio is likely to grow to 7.07 this year. During the period from 2010 to 2024, ProQR Therapeutics POCF Ratio destribution of quarterly values had r-value of  0.81 from its regression line and median of (8.25). View All Fundamentals
 
POCF Ratio  
First Reported
2010-12-31
Previous Quarter
6.73455889
Current Value
7.07
Quarterly Volatility
44.67641026
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check ProQR Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ProQR Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 1.4 M, Total Revenue of 6.8 M or Research Development of 30.4 M, as well as many indicators such as Price To Sales Ratio of 21.16, Dividend Yield of 0.0 or PTB Ratio of 3.68. ProQR financial statements analysis is a perfect complement when working with ProQR Therapeutics Valuation or Volatility modules.
  
Check out the analysis of ProQR Therapeutics Correlation against competitors.

Latest ProQR Therapeutics' Pocfratio Growth Pattern

Below is the plot of the Pocfratio of ProQR Therapeutics BV over the last few years. It is ProQR Therapeutics' POCF Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ProQR Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Pocfratio10 Years Trend
Slightly volatile
   Pocfratio   
       Timeline  

ProQR Pocfratio Regression Statistics

Arithmetic Mean(31.27)
Coefficient Of Variation(142.90)
Mean Deviation37.73
Median(8.25)
Standard Deviation44.68
Sample Variance1,996
Range109
R-Value0.81
Mean Square Error742.08
R-Squared0.65
Significance0.0003
Slope8.08
Total Sum of Squares27,944

ProQR Pocfratio History

2024 7.07
2023 6.73
2022 -3.61
2021 -17.38
2020 -3.66
2019 -8.25
2018 -15.27

About ProQR Therapeutics Financial Statements

ProQR Therapeutics shareholders use historical fundamental indicators, such as Pocfratio, to determine how well the company is positioned to perform in the future. Although ProQR Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in ProQR Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on ProQR Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
POCF Ratio 6.73  7.07 

Pair Trading with ProQR Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ProQR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProQR Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against ProQR Stock

  0.84MTEM Molecular TemplatesPairCorr
  0.83ME 23Andme HoldingPairCorr
  0.83MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
  0.8TPST Tempest TherapeuticsPairCorr
  0.78AGL agilon healthPairCorr
The ability to find closely correlated positions to ProQR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ProQR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ProQR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ProQR Therapeutics BV to buy it.
The correlation of ProQR Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ProQR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ProQR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ProQR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for ProQR Stock Analysis

When running ProQR Therapeutics' price analysis, check to measure ProQR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProQR Therapeutics is operating at the current time. Most of ProQR Therapeutics' value examination focuses on studying past and present price action to predict the probability of ProQR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProQR Therapeutics' price. Additionally, you may evaluate how the addition of ProQR Therapeutics to your portfolios can decrease your overall portfolio volatility.